LENZ now combines a significantly strengthened balance sheet with a newly approved, differentiated product addressing a very common vision problem. Liquidity is high, debt is minimal, and equity has swung from negative to strongly positive after substantial capital inflows. Clinically, VIZZ offers a clear value proposition with rapid and durable improvement in near vision while largely preserving distance vision, and it is backed by strong patent protection and likely regulatory exclusivity. The company has already advanced a second late-stage candidate, signaling some depth in its core technology.

On the other side, the company remains loss-making with no history of sustained revenue generation, and cash flow is decidedly negative. Operating expenses, especially overhead, have risen significantly, and the business is now highly dependent on a successful commercial rollout of a single primary product. Competition in presbyopia is active, including from large, well-capitalized firms, and real-world adoption, pricing power, and reimbursement are uncertain. The pipeline outside of presbyopia-focused assets is limited, so any setback with VIZZ or LNZ101 would weigh heavily on the company’s prospects.

LENZ appears to be at an inflection point, shifting from a development-stage biotech to an early commercial ophthalmology company. Financially, it has the cash and balance sheet strength to fund a meaningful launch and some additional development, but not yet a self-sustaining business model. The medium-term trajectory will largely depend on how quickly VIZZ can gain traction and how effectively LENZ can convert its scientific advantages into durable market share while managing costs. If commercialization progresses well, the company’s financial profile could gradually normalize; if uptake disappoints or competition intensifies, LENZ may remain reliant on capital markets and face pressure to reshape its strategy or pipeline.